Tekla Capital Management LLC Prometheus Biosciences, Inc. Transaction History

Tekla Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$103.46 - $126.29 $1.27 Million - $1.55 Million	12,301 Added 32.17%	50,538 $5.42 Million
Q4 2022 Feb 10, 2023	BUY	$36.06 - $117.21 $242,755 - $789,057	6,732 Added 21.37%	38,237 $4.21 Million
Q3 2022 Nov 01, 2022	SELL	$28.17 - $59.01 $498,327 - $1.04 Million	-17,690 Reduced 35.96%	31,505 $1.86 Million
Q2 2022 Jul 29, 2022	BUY	$22.39 - $38.94 $606,321 - $1.05 Million	27,080 Added 122.45%	49,195 $1.39 Million
Q1 2022 May 13, 2022	BUY	$30.13 - $50.0 $666,324 - $1.11 Million	22,115 New	22,115 $835,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.